The limitations of transferring evidence from clinical trials to the care of individual patients

High Blood Pressure and Cardiovascular Prevention

Volumn 12, Issue 1, 2005, Pages 5-7

  Alderman, Michael H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; PLACEBO;

ADVERSE DRUG REACTION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 22744434113     PISSN: 11209879     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151642-200512010-00002     Document Type: Review

References (9)

1. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-38
2. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202:1028-34
3. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74
4. Alderman MH. High blood pressure: do we really know whom to treat and how? N Engl J Med 1977; 296: 753-5
5. Madhavan S, Alderman MH. The potential effect of blood pressure reduction on cardiovascular disease: a cautionary note. Arch Intern Med 1981; 141: 1583-6
6. Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365: 434-41
7. Alderman MH. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med 1993; 119: 329-35
8. Deary AJ, Schumann AL, Murfet H, et al. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2002; 20: 771-7
9. Alderman MH, Madhavan S, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-104